Canaccord Genuity Group Forecasts Strong Price Appreciation for LifeStance Health Group (NASDAQ:LFST) Stock

LifeStance Health Group (NASDAQ:LFST) had its price objective increased by equities research analysts at Canaccord Genuity Group from $9.00 to $10.00 in a report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 43.97% from the company’s previous close.

A number of other research firms have also weighed in on LFST. UBS Group increased their price objective on shares of LifeStance Health Group from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday. Zacks Research cut LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 5th. Wall Street Zen upgraded LifeStance Health Group from a “hold” rating to a “buy” rating in a report on Sunday, February 8th. BMO Capital Markets assumed coverage on LifeStance Health Group in a research note on Thursday, November 13th. They set an “outperform” rating and a $8.00 price target for the company. Finally, Barclays initiated coverage on LifeStance Health Group in a report on Tuesday, December 9th. They set an “overweight” rating and a $8.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, LifeStance Health Group currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.67.

LifeStance Health Group Trading Down 6.3%

NASDAQ:LFST traded down $0.46 during midday trading on Thursday, hitting $6.95. 8,131,978 shares of the company traded hands, compared to its average volume of 1,962,015. The firm has a market capitalization of $2.70 billion, a P/E ratio of -231.53 and a beta of 1.12. The firm’s fifty day moving average is $7.12 and its 200-day moving average is $6.18. LifeStance Health Group has a 12-month low of $3.74 and a 12-month high of $8.30. The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.02). LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The firm had revenue of $382.20 million for the quarter, compared to the consensus estimate of $378.51 million. During the same quarter last year, the firm earned ($0.01) EPS. The company’s revenue was up 17.4% on a year-over-year basis. On average, sell-side analysts predict that LifeStance Health Group will post -0.18 EPS for the current year.

LifeStance Health Group announced that its board has authorized a stock repurchase plan on Wednesday, February 25th that permits the company to repurchase $100.00 million in shares. This repurchase authorization permits the company to repurchase up to 3.6% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity

In other LifeStance Health Group news, Director Robert Bessler sold 119,942 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $7.04, for a total transaction of $844,391.68. Following the completion of the sale, the director owned 1,318,983 shares in the company, valued at $9,285,640.32. This represents a 8.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ann Varanakis sold 50,000 shares of LifeStance Health Group stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total value of $345,000.00. Following the completion of the transaction, the insider owned 315,610 shares in the company, valued at $2,177,709. This represents a 13.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 270,086 shares of company stock worth $1,891,264. 3.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On LifeStance Health Group

Institutional investors have recently added to or reduced their stakes in the stock. Silversmith Partners I GP LLC bought a new position in LifeStance Health Group in the fourth quarter worth about $100,842,000. AustralianSuper Pty Ltd purchased a new stake in LifeStance Health Group during the third quarter valued at approximately $17,056,000. Vanguard Group Inc. boosted its stake in LifeStance Health Group by 21.1% in the fourth quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock valued at $124,608,000 after acquiring an additional 3,086,506 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in LifeStance Health Group by 62.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock worth $26,363,000 after purchasing an additional 1,839,465 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of LifeStance Health Group by 27.2% during the third quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company’s stock worth $45,998,000 after purchasing an additional 1,790,694 shares in the last quarter. Institutional investors own 85.50% of the company’s stock.

Trending Headlines about LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Q4 / FY2025 results and 2026 outlook show solid demand and margin progress: revenue +17% in Q4 to $382.2M, positive net income and a meaningful rise in Adjusted EBITDA; management guided 2026 revenue to $1.615B–$1.655B and raised EBITDA expectations, giving a clear growth + profitability story that supports longer‑term upside. LifeStance Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Board authorized a $100M share repurchase program (up to ~3.6% of shares), a capital-allocation move that signals management believes shares are undervalued and can support the stock over time. Press Release
• Positive Sentiment: Analyst support increased: UBS raised its price target to $12 with a Buy and KeyCorp lifted its target to $9 with an Overweight rating — both represent meaningful upside from current levels and can help sustain demand from institutional buyers. Analyst Price Target Raises
• Neutral Sentiment: Company reiterated 1Q26 revenue range ($380M–$400M) and provided detailed center‑margin / EBITDA targets — helpful for modeling but not a surprise given the Q4 print. Earnings Presentation
• Negative Sentiment: Selling stockholders launched a secondary offering of 25M shares (company receives no proceeds), which creates near‑term selling pressure and increases float — a likely key reason for downward pressure despite operational strength. Secondary Public Offering
• Negative Sentiment: EPS missed some sell‑side expectations (reported ~$0.03 vs. consensus ~$0.05), which—combined with the secondary offering and heavy insider/selling‑holder activity reported in filings—has likely amplified intraday weakness even though revenue beat and margins improved. Earnings Call Transcript

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.